USPTO Examiner KOSACK JOSEPH R - Art Unit 3991

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17104166COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESISNovember 2020February 2024Allow3911YesNo
16999818STRONGLY LEWIS ACIDIC METAL-ORGANIC FRAMEWORKS FOR CONTINUOUS FLOW CATALYSISAugust 2020March 2024Allow4321NoNo
16265386SOLID-SUPPORTED CATALYST FOR CROSS-COUPLINGFebruary 2019June 2019Allow410NoNo
16265425ARYL HALIDE CROSS-COUPLING METHOD AND PRODUCT MADE THEREFROMFebruary 2019June 2019Allow410NoNo
16210163[4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOFDecember 2018May 2019Allow510NoNo
16210066PROCESS FOR PREPARING CYCLOPHOSPHAMIDE, INTERMEDIATES, AND MONOHYDRATE THEREOFDecember 2018September 2019Allow1000NoNo
16078396TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOFAugust 2018August 2019Allow1200NoNo
16076797SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDESAugust 2018July 2019Allow1100NoNo
16054713BIOFILM INHIBITING COMPOSITIONS ENHANCING WEIGHT GAIN IN LIVESTOCKAugust 2018March 2019Allow810NoNo
15922376BETA-LACTAMASE INHIBITORSMarch 2018January 2019Allow1010NoNo
15759600MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASEMarch 2018July 2019Allow1610NoNo
15915415Boron-Containing Diacylhydrazine CompoundsMarch 2018October 2019Allow1911NoNo
15748557CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORSJanuary 2018October 2019Allow2011NoNo
15864650GOLD(I) COMPLEXES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING PROLIFERATIVE DISORDERSJanuary 2018November 2018Allow1110NoNo
15801781NOVEL CRYSTALLINE FORMSNovember 2017August 2019Allow2120NoNo
15532298LUMINESCENT PALLADIUM(0) AND PLATINUM(0) CARBENE COMPLEXES FOR OLEDSJune 2017June 2018Allow1200NoNo
15488762SELF-ASSEMBLY OF NANOSTRUCTURESApril 2017November 2019Allow3141NoNo
15459693Zinc or Copper (II) Salt and Use Thereof as a BiocideMarch 2017December 2017Allow920NoNo
15452839METATHESIS CATALYSTMarch 2017September 2017Allow710NoNo
15362997SOLID-SUPPORTED PALLADIUM (II) COMPLEX AS A HETEROGENEOUS CATALYST FOR CROSS COUPLING REACTIONS AND METHODS THEREOFNovember 2016January 2019Allow2610NoNo
15314256Bi-Nuclear Main Group Metal Phosphorescent EmitterNovember 2016August 2019Allow3221NoNo
15353453PROTECTIVE LAYERS PRODUCED BY SOL GEL PROCESSESNovember 2016August 2019Allow3312NoNo
15353256COLOR CONVERSION FILMS PRODUCED BY UV CURING PROCESSESNovember 2016August 2019Allow3312NoNo
15353509PROTECTIVE LAYERS PRODUCED BY UV CURING PROCESSESNovember 2016August 2019Allow3312NoNo
15353373RED ENHANCEMENT IN WHITE LED DISPLAYS USING UV-CURED COLOR CONVERSION FILMSNovember 2016August 2019Allow3312NoNo
15282636METHOD FOR TREATING PROSTATE CANCER AND/OR GASTROINTESTINAL CANCERSeptember 2016January 2017Allow400YesNo
15281735METHOD FOR TREATING A CANCER WITH A MIXED LIGAND GOLD(III) COMPLEXES AS ANTI-CANCER AGENTSSeptember 2016January 2017Allow310NoNo
15273582PROCESS FOR PREPARING IMIDAZOLIUM BASED IONIC LIQUIDS WITH DI-POLYMERIZED OXIRANE BASESeptember 2016February 2018Allow1710NoNo
15126422DESIGN, SYNTHESIS, AND BIOLOGICAL ACTIVITY OF PLATINUM-BENZ[C]ACRIDINE HYBRID AGENTS AND METHODS ASSOCIATED THEREWITHSeptember 2016October 2017Allow1300NoNo
15164002PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSMay 2016January 2017Allow820NoNo
15092906PHOSPHORESCENT ORGANOMETALLIC IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICEApril 2016July 2018Allow2711NoNo
15027008Method for Preparation of Cyano Compounds of the 13th Group with a Lewis AcidApril 2016June 2016Allow300NoNo
15081308PALLADIUM(II) COMPLEX FOR CATALYZING SONOGASHIRA COUPLING REACTIONS AND A METHOD THEREOFMarch 2016November 2016Allow810NoNo
14916547PHOTOLABILE LINKER FOR THE SOLID-PHASE SYNTHESIS OF HYDRAZIDES AND PYRANOPYRAZOLESMarch 2016August 2017Allow1710NoNo
15056580MOLECULAR SWITCHES BASED ON CIS/TRANS ISOMERIZATION OF BF2-COORDINATED AZO COMPOUNDSFebruary 2016October 2017Allow1910NoNo
14907147PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUNDJanuary 2016May 2018Allow2811NoNo
14902514PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPYDecember 2015February 2018Allow2611NoNo
14898410METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONSDecember 2015May 2016Allow500NoNo
14892451RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTSNovember 2015September 2017Allow2200NoNo
14941167METHOD FOR PRODUCING LINEAR PENTENENITRILENovember 2015July 2016Allow810NoNo
14855646BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDSSeptember 2015December 2017Allow2711NoNo
14850063MIXED LIGAND GOLD(III) COMPLEXES AS ANTI-CANCER AGENTSSeptember 2015August 2016Allow1100NoNo
14774570ORGANIC OLIGOMERS OF ACYLGLYCEROLSeptember 2015January 2018Allow2820NoNo
14834420PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSAugust 2015February 2016Allow610NoNo
14798071MIXED LIGAND GOLD(III) COMPLEXES AND METHODS THEREOFJuly 2015July 2016Allow1200NoNo
14759778ORGANIC DYE FOR A DYE SENSITIZED SOLAR CELLJuly 2015August 2017Allow2621NoNo
14651239Process for Preparing Asymmetrical Imidazolium SaltsJuly 2015February 2017Allow2010NoNo
14758421DITHIENYLPYRROLE-BASED BIOSENSORS AND METHODS FOR THEIR PREPARATION AND USEJune 2015September 2017Allow2701NoNo
14441304DIHYDROTHIOPHENE DERIVATIVES AS INSECTICIDAL COMPOUNDSMay 2015August 2019Allow5151NoYes
14705527COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENESMay 2015December 2015Allow710NoNo
14705627N-HETEROCYCLIC CARBENE GOLD COMPLEXES WITH ANTICANCER PROPERTIES AND METHODS OF USE THEREOFMay 2015December 2016Allow2010NoNo
14669606ORGANIC LIGHT-EMITTING DEVICE AND METHOD OF PRODUCING THE SAMEMarch 2015March 2019Allow4840YesNo
14611943PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSFebruary 2015April 2015Allow300NoNo
14610519METHODS FOR PREPARING RUTHENIUM CARBENE COMPLEX PRECURSORS AND RUTHENIUM CARBENE COMPLEXESJanuary 2015December 2016Allow2310NoNo
14417934BORON-CONTAINING 5-ARYLIDENE-3,5-DIHYDRO-4H-IMIDAZOL-4-ONESJanuary 2015July 2015Allow610NoNo
14412888Polysilylated Organosilane CompoundsJanuary 2015October 2017Allow3311NoNo
14572015Soft Protease Inhibitors and Pro-Soft Forms ThereofDecember 2014July 2015Allow710NoNo
14546661PROCESS FOR THE PREPARATION OF PERFLUOROALKYLCYANO- OR PERFLUOROALKYLCYANOFLUOROBORATESNovember 2014August 2015Allow910NoNo
14507453BORON-CONTAINING SMALL MOLECULESOctober 2014May 2015Allow810NoNo
14387890COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASESeptember 2014February 2016Allow1710NoNo
14121568SYNTHESIS AND STRUCTURE OF 3,5-DIAMINO-2,6-DI-(TERT-BUTYI-NNO-AZOXY) PYRAZINE AS A CRITICAL INTERMEDIATE IN THE SYNTHESIS OF A NOVEL ENERGETIC COMPOUNDSeptember 2014January 2017Allow2810NoNo
14478581METHODS FOR PRODUCING BORYLATED ARENESSeptember 2014June 2018Allow4522YesNo
14467625PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSAugust 2014September 2015Allow1320NoNo
14267455METHODS FOR PREPARING RUTHENIUM CARBENE COMPLEX PRECURSORS AND RUTHENIUM CARBENE COMPLEXESMay 2014January 2017Allow3211NoNo
14353511SILYLATED AZULENYL NITRONE SPIN TRAPS AS CHROMOTROPIC SUPEROXIDE DETECTORSApril 2014May 2015Allow1300NoNo
14348407RUTHENIUM POLYMERISATION CATALYSTSMarch 2014July 2017Allow3921YesNo
14226884AZO MEDIATORS AND METHODS OF USE THEREOFMarch 2014August 2017Allow4022NoNo
14343235METAL NICKEL-IMIDAZOLATE CHIRAL NANO CLATHRATE COMPLEX AND PREPARATION METHOD THEREOFMarch 2014February 2015Allow1210NoNo
14176571METHOD FOR PURIFYING A CRUDE PNPNH COMPOUNDFebruary 2014September 2015Allow1910NoNo
14174669COMPOSITIONS AND METHODS FOR CYTOPROTECTIONFebruary 2014August 2014Allow610NoNo
14000116Process to Obtain a Trifluoromethylating CompositionJanuary 2014February 2017Allow4231NoNo
14232673COMPOUNDS CONTAINING ALKYL-ALKOXY-CYANO-BORATE ANIONSJanuary 2014May 2014Allow400NoNo
14129596PHOSPHORIC ACID ESTER DERIVATIVESDecember 2013April 2015Allow1600NoNo
14109475Cyanine compounds and their application as quenching compoundsDecember 2013June 2015Allow1810NoNo
14118158ZEOLITE POROUS METAL BIS(IMIDAZOLE) COORDINATION POLYMERS AND PREPARATION METHOD THEREOFNovember 2013February 2015Allow1510NoNo
14041201Soft Protease Inhibitors and Pro-Soft Forms ThereofSeptember 2013September 2014Allow1110YesNo
13966613EPOTHILONE DERIVATIVESAugust 2013August 2014Allow1221NoNo
13954100NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICSJuly 2013January 2014Allow610NoNo
13947222RADIOTRACER PRECURSOR BANI FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAMEJuly 2013January 2015Allow1810NoNo
13927295BACKFLUORINATED NHC CARBENES AND COMPLEXESJune 2013November 2015Allow3010NoNo
13923540PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOFJune 2013November 2014Allow1720NoYes
13920502FUSED THIOPHENES AND METHODS FOR MAKING AND USING SAMEJune 2013August 2013Allow200NoNo
13988734BODIPY STRUCTURE FLUORESCENCE DYE FOR NEURAL STEM CELL PROBEMay 2013July 2014Allow1400NoNo
13880972DIPHOSPHONATE COMPOUND AND A METHOD FOR PREPARING THE SAME AND AN APPLICATION OF THE SAMEApril 2013January 2015Allow2110NoNo
13879650Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory ConditionsApril 2013June 2015Allow2610NoNo
13876414ELECTROLYTE FORMULATIONSMarch 2013September 2014Allow1710NoNo
13780939Precursors And Methods For The Selective Deposition Of Cobalt And Manganese On Metal SurfacesFebruary 2013April 2015Allow2510YesNo
13744494METHOD FOR PRODUCING 2-CYANOACETIC ACID ANHYDRIDE AND FURTHER REACTION PRODUCTS THEREOFJanuary 2013September 2014Allow2000NoNo
13809354SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITSJanuary 2013July 2015Allow3010NoNo
13714259METHOD OF PREPARING RADIOISOTOPE NANOSTRUCTURE WITH LIGAND-METAL FRAMEWORK AND APPLICATIONDecember 2012January 2015Allow2500NoNo
13678576BORON-CONTAINING SMALL MOLECULESNovember 2012June 2014Allow1900NoNo
13521969PROCESS FOR PREPARATION OF RUTHENIUM-BASED CARBENE CATALYSTS WITH CHELATING ALKYLIDENE LIGANDSOctober 2012August 2015Allow3730NoNo
13626358ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODSSeptember 2012May 2013Allow800NoNo
13617790SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOFSeptember 2012June 2013Allow900NoNo
13582653MONONUCLEAR METAL COMPLEX, HYDROGENATION REDUCTION CATALYST, DEHYDROGENATION CATALYST, METHOD FOR PRODUCING HYDROGENATION REDUCTION PRODUCT, METHOD FOR PRODUCING HYDROGEN (H2), AND METHOD FOR PRODUCING DEHYDROGENATION REACTION PRODUCTSeptember 2012July 2015Allow5711NoNo
13591117PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSAugust 2012July 2014Allow2310NoNo
13503292METHOD FOR PREPARING ORGANIC/INORGANIC HYBRID FUNCTIONALIZED SOLIDS HAVING A TRIAZOLE RINGAugust 2012September 2014Allow2900NoNo
13522526PROCESS FOR THE PREPARATION OF PERFLUOROALKYLCYANO- OR PERFLUOROALKYLCYANOFLUOROBORATESJuly 2012August 2014Allow2510NoNo
13522545ELECTROLYTE FORMULATIONSJuly 2012June 2014Allow2310NoNo
13522598COMPOUNDS CONTAINING PERFLUOROALKYL-CYANO-ALKOXY-BORATE ANIONS OR PERFLUOROALKYL-CYANO-ALKOXY-FLUORO-BORATE ANIONSJuly 2012May 2014Allow2200NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSACK, JOSEPH R.

Strategic Value of Filing an Appeal

Total Appeal Filings
24
Allowed After Appeal Filing
11
(45.8%)
Not Allowed After Appeal Filing
13
(54.2%)
Filing Benefit Percentile
74.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 45.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner KOSACK, JOSEPH R - Prosecution Strategy Guide

Executive Summary

Examiner KOSACK, JOSEPH R works in Art Unit 3991 and has examined 369 patent applications in our dataset. With an allowance rate of 99.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner KOSACK, JOSEPH R's allowance rate of 99.2% places them in the 92% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KOSACK, JOSEPH R receive 1.56 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KOSACK, JOSEPH R is 30 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -4.7% benefit to allowance rate for applications examined by KOSACK, JOSEPH R. This interview benefit is in the 7% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 39.1% of applications are subsequently allowed. This success rate is in the 89% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 61.8% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 100% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 100% percentile among all examiners. Of these withdrawals, 86.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 47.8% are granted (fully or in part). This grant rate is in the 41% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 23.8% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.